VX15-770-126: A Phase 3, 2-Arm, Open-label Study to Evaluate the Safety and Pharmacodynamics of Long-term Ivacaftor Treatment in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation and Have

Project: Research project

Project Details

StatusActive
Effective start/end date9/11/1712/31/20

Funding

  • Vertex Pharmaceuticals Incorporated